Dasatinib
bms
['cml']
#eha2022 #cml 5 yrs follow up results from dasfree trial: approximately 50% of patient remained treatment free at 5 years after first line dasatinib. 
Assistant Professor @MayoCancerCare @MayoClinic Alumni @MDAndersonNews. Interest in Acute Leukemia and Chronic myeloid disorders. Views are my own